Question 1

What is MOTS-c?

Accepted Answer

MOTS-c is one of a handful of peptides the body encodes inside its mitochondria rather than in the cell nucleus, which is unusual enough that it went unnoticed until 2015. The name stands for mitochondrial open reading frame of the 12S rRNA type-c — an unwieldy label for a molecule of just 16 amino acids. Mitochondria, the compartments inside a cell that generate energy, carry their own short length of DNA, and the instructions for MOTS-c are written there. It is therefore an endogenous signal, meaning one the body already manufactures, rather than a molecule borrowed from another organism. The peptide is detectable in multiple tissues and in blood plasma, and a 2023 review reports that plasma concentrations decline with advancing age. Under metabolic stress, MOTS-c relocates into the nucleus and alters which genes a cell expresses. The 2015 paper that first characterised the peptide identified skeletal muscle as its primary target organ.

Question 2

Has MOTS-c been studied in people?

Accepted Answer

Yes, though not in the sense the question usually intends. The human studies measured how much MOTS-c a person already carries. None of them gave anyone more. In 107 patients undergoing cardiopulmonary bypass, the heart-lung machine used during cardiac surgery, MOTS-c concentrations were significantly reduced in those who developed acute lung injury. In that same surgical population, the increment in serum MOTS-c during the first 24 hours outperformed conventional markers at predicting which patients developed respiratory distress. People with type 1 diabetes and people with type 2 diabetes both carry less MOTS-c than healthy controls. That work establishes the peptide as a real human signal that moves with illness. It does not tell you what giving more of it does. Three studies naming MOTS-c are registered on ClinicalTrials.gov, and two only measure it as a marker. The only one that gives the peptide is a Phase 2 study in adults with prediabetes and excess body weight. It is listed as recruiting and has not yet reported.

Question 3

How often is MOTS-c given in studies?

Accepted Answer

No established schedule exists for a person, because no completed trial has given MOTS-c to one. The animal record is the only available reference, and it is worth reading as experimental parameters rather than as instruction. Rats with induced vascular calcification were injected with MOTS-c at 5 mg/kg once daily for 4 weeks. Mice with gestational diabetes received the peptide daily throughout pregnancy. In a sepsis experiment, mice received a single 20 mg/kg dose four hours before the injury. In mice with muscular dystrophy, 500 micrograms was given weekly for 3 weeks and then monthly for 3 months. The pattern across this literature is mostly daily dosing, in milligrams per kilogram of body weight, for two to four weeks. Those figures describe an experiment rather than a protocol, and animal amounts do not convert into human ones. Before any of it becomes a quantity a person could measure out, the MOTS-c dosage page has to get from milligrams per kilogram of rat to a number on a syringe. What can be verified about a vial sold under this name, and what a certificate of analysis does not establish, is set out at the MOTS-c sourcing page.

Question 4

Is there a safety record for MOTS-c?

Accepted Answer

No adverse-effect profile exists for people, because no trial among the research behind this page has given MOTS-c to a person and watched what followed. A 2026 review in Sports Medicine states the position for this whole class of peptides: favourable metabolic and tissue-repair outcomes in animal models, scarce rigorous human safety data, and real potential for serious harm. The individual animal papers mostly report nothing adverse. Months of MOTS-c given alongside a muscular dystrophy compound improved muscle function in mdx mice without detectable toxicity. In hepatitis B work done in cells and in mice, liver function improved without notable toxicity. That is weaker than it appears. Seeing no toxicity in a brief rodent experiment is not the same as having a safety profile. Nobody was looking for rare or late effects. One finding does point the other way. A 2018 report described humanin and MOTS-c both driving senescent cells, meaning worn-out cells that have stopped dividing, to secrete more inflammatory signals.

Question 5

Does MOTS-c get rid of belly fat?

Accepted Answer

No study among the research behind this page has measured fat loss in people administered MOTS-c. What exists instead is a genuine signal in animals: in the 2015 discovery work, MOTS-c treatment in mice prevented diet-induced obesity, alongside insulin resistance arising from ageing and from a high-fat diet. Read that carefully. It describes prevention, in animals put on a controlled high-fat diet by the researchers running the study. It does not describe fat loss in a person already carrying excess weight. Those are different questions, and the second has not been asked. A 2022 review supplies a plausible route for the first result. Exogenous MOTS-c, meaning peptide given from outside, stimulates heat generation in white fat under the skin and thereby raises energy expenditure. Nothing in these sources documents a change in waist circumference, visceral fat or body composition in a human being.

Question 6

How long does it take for MOTS-c to work?

Accepted Answer

No study among the research behind this page measures an onset time in a person. The study durations are the only anchor, and they vary enormously with what was being watched. In a mouse sepsis model, one dose given four hours before the injury increased survival and reduced brain-damage scores. In rats, the vascular calcification result emerged after 4 weeks of daily injections. In mice with muscular dystrophy, the muscle-protein result needed 3 weeks of weekly dosing, then 3 months of monthly dosing. So the animal range runs from hours to months, depending entirely on the outcome being measured. A biochemical marker shifting and a body visibly changing composition are different questions, and nothing in these sources puts a clock on the second.

Question 7

How does MOTS-c make you feel?

Accepted Answer

No study among the research behind this page records how it feels. In the studies behind this page, nobody asked a participant how they felt while receiving MOTS-c, so there is nothing on record about energy, mood or sleep. The nearest thing to it concerns exercise. A 2022 review reports that MOTS-c concentrations increase in skeletal muscle, in the systemic circulation and in the hypothalamus following exercise, and that systemic administration increases exercise performance. That is the review's interpretation of the underlying experiments, and these sources contain no human performance trial. One human experiment is directly relevant and distinctly unglamorous: during one-legged knee-extensor exercise, MOTS-c rose in the fluid surrounding working muscle, yet the leg showed no net uptake or release of the peptide, suggesting that muscle may not be the source of circulating MOTS-c. Knowing that a peptide rises during exercise does not tell you what taking it feels like. What people report online, and what weight any of it can carry, is examined at the MOTS-c results page.

Question 8

Will I lose weight on MOTS-c?

Accepted Answer

The weight measurements in this literature are not the measurements the question is about. In the rat vascular calcification experiment, body weight was recorded as a routine physiological check alongside blood pressure and heart rate, not as the outcome under investigation. In the gestational diabetes mice, the weight that moved was the birth weight of the offspring. Two reviews summarise the broader claim: MOTS-c prevents obesity, lowers insulin resistance and assists skeletal muscle in handling glucose. Every one of those results originates in rodents or in cultured cells. Preventing weight gain in an animal held on a fixed experimental diet and losing weight as an adult who already carries it are different questions. The second has not been studied, and no study among the research behind this page documents a weight change in a person administered MOTS-c.

Question 9

What peptide should I stack with MOTS-c?

Accepted Answer

No study among the research behind this page evaluates a stack in the sense the question intends. The combinations that do appear are laboratory pairings, each built for one disease model. MOTS-c was paired with a muscular dystrophy compound in mice, where its contribution was to elevate muscle energy production so the other compound was absorbed more effectively, which is a delivery effect, not two benefits adding up. MOTS-c was paired with a humanin analogue to protect sperm production in male mice following chemotherapy. It has been attached to a nanoparticle engineered to target ageing muscle in mice. A vitamin called PQQ, short for pyrroloquinoline quinone, increased the mouse's own MOTS-c in irradiated lung tissue. Together they show that MOTS-c can be combined without the combination failing in an animal. That is not the same as a stack doing anything for a person.

Question 10

What is the difference between MOTS-c and NAD+?

Accepted Answer

None of the sources supporting this page compares MOTS-c with NAD+, and none evaluates the two in combination. That is worth stating plainly rather than filling the vacancy with speculation. What can be established is what MOTS-c is: a peptide of 16 amino acids, encoded within mitochondrial DNA, which relocates into the nucleus under metabolic stress and alters which genes a cell expresses. It functions as a regulatory message rather than as metabolic fuel or as raw material. Any head-to-head comparison you encounter, concerning which produces more energy, which persists longer, or whether the two belong together, is not derived from this literature. Those are different questions, and the research we cite contains no investigation that would answer them.

Question 11

Does MOTS-c do anything for muscle?

Accepted Answer

Skeletal muscle is where the animal evidence is strongest. The 2015 paper identified it as the primary target organ, and a 2024 study established part of the mechanism: MOTS-c binds CK2, an enzyme that acts as a switch inside cells. In that experiment, MOTS-c administered to mice prevented muscle wasting and increased glucose uptake into muscle, and both effects disappeared when CK2 was blocked — which is the result you want, because it ties the benefit to the mechanism rather than to coincidence. A 2026 experiment in two transgenic mouse strains reported that MOTS-c improved the efficiency with which muscle mitochondria generate energy. The account hangs together, and it sits entirely in mice. Note what was actually measured, too: preventing wasting in a diseased animal is a different question from adding muscle to a healthy adult. No trial among the research behind this page has measured strength, muscle size or endurance in a person given MOTS-c.

Question 12

Does MOTS-c work the same in everyone?

Accepted Answer

There is one indication that it might not, and it concerns genetics rather than dosing. Some individuals carry a naturally occurring variant of MOTS-c designated K14Q. In laboratory work, K14Q binds CK2 poorly and fails to produce the effects that ordinary MOTS-c generates. In population data reported in the same 2024 paper, male carriers of K14Q showed elevated risk of sarcopenia, meaning age-related muscle loss, and of type 2 diabetes, in a pattern dependent on age and on physical activity. Female carriers showed lower risk of type 2 diabetes at particular ages. Two conclusions follow, and the obvious one is not among them. The finding establishes that a person's own circulating MOTS-c matters for human metabolism. It does not tell you who responds to MOTS-c given from outside, because that has not been tested in anyone.

Question 13

How is MOTS-c thought to work?

Accepted Answer

The short version is that MOTS-c is a stress message sent from the mitochondria to the rest of the cell. The 2015 discovery work found that the peptide blocks the folate cycle, a chemical loop cells use to build new DNA components, and that this activates AMPK, a sensor that registers when a cell is running low on energy. A 2023 review describes the other half of the mechanism: under metabolic stress the peptide moves into the nucleus and changes which genes the cell expresses. A second 2023 review lists the genes implicated most often, including GLUT4, the transporter skeletal muscle uses to draw glucose inward. Laboratory work continues past that point, into models of osteoarthritis, sepsis and lung injury, none of which has yet reached a person. That is the mechanism in outline; the receptor-level detail sits at the MOTS-c benefits page.

MOTS-c